Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06112782Not ApplicableCompleted

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

Role: collaborator

NCT01111994Phase 4Unknown

Efficacy & Safety of Clindamycin and Tretinoin in Acne

Role: lead

NCT01111981Phase 4Unknown

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

Role: lead

NCT00927771Phase 4Unknown

Azelaic Acid Versus Hydroquinone in Melasma

Role: lead

All 4 trials loaded